EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 348 (2026) EPJ Web Conf., 348 (2026) 01013 References
Open Access
Issue
EPJ Web Conf.
Volume 348, 2026
3rd International Conference on Innovations in Molecular Structure & Instrumental Approaches (ICMSI 2026)
Article Number 01013
Number of page(s) 17
Section Life Science
DOI https://doi.org/10.1051/epjconf/202634801013
Published online 21 January 2026
  1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am J Med Sci. 105, 487–511 (1893). doi: 10.1097/00000441-189305000-00001 [Google Scholar]
  2. Kienle GS. Fever in cancer treatment: Coley's therapy and epidemiologic observations. Glob Adv Health Med. 1(1), 92–100 (2012). doi: 10.7453/gahmj.2012.1.1.018 [Google Scholar]
  3. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 13, 1–27 (1970). doi: 10.1159/000402853 [Google Scholar]
  4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3, (11):991–8 (2002). doi: 10.1038/ni1102-991 [Google Scholar]
  5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12, (4):252–64 (2012). doi: 10.1038/nrc3239 [Google Scholar]
  6. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 125, (9):3384–91 (2015). doi: 10.1172/JCI80011 [Google Scholar]
  7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271, (5256):1734–6 (1996). doi: 10.1126/science.271.5256.1734 [Google Scholar]
  8. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, (11):3887–95 (1992). doi: 10.1002/j.1460-2075.1992.tb05481.x [Google Scholar]
  9. Freeman GJ, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192, (7):1027–34 (2000). doi: 10.1084/jem.192.7.1027 [Google Scholar]
  10. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 359, (6382):1350–5 (2018). doi: 10.1126/science.aar4060 [Google Scholar]
  11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, (8):711–23 (2010). doi: 10.1056/NEJMoa1003466 [Google Scholar]
  12. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364, (26):2517–26 (2011). doi: 10.1056/NEJMoa1104621 [Google Scholar]
  13. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1, (5):405–13 (1994). doi: 10.1016/1074-7613(94)90071-x [Google Scholar]
  14. Read S, Greenwald R, Izcue A, Robinson N, et al. Blockade of CTLA-4 on both effector and regulatory T cells contributes to the antitumor activity of anti-CTLA-4 antibodies. J Immunol. 177, (12):8200–7 (2006). doi: 10.4049/jimmunol.177.12.8200 [Google Scholar]
  15. Linsley PS, Greene JL, Brady WA, Bajorath J, Ledbetter JA, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 174, (3):561–9 (1991). doi: 10.1084/jem.174.3.561 [Google Scholar]
  16. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 13, (4):227–42 (2013). doi: 10.1038/nri3405 [Google Scholar]
  17. van der Merwe PA, Davis SJ, Shaw AS, et al. Affinity and kinetic analysis of the interaction of the cell adhesion molecules CD2 and CD48. EMBO J. 12, (13):4945–54 (1993). doi: 10.1002/j.1460-2075.1993.tb06393.x [Google Scholar]
  18. Egen JG, Allison JP. Cytotoxic T lymphocyte-associated antigen 4 signaling inhibits T cell activation by stopping T cell cycle progression. J Exp Med. 196, (3):335–46 (2002). doi: 10.1084/jem.20020389 [Google Scholar]
  19. Simpson Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 182, (2):459–65 (1995). doi: 10.1084/jem.182.2.459 [Google Scholar]
  20. TR, Li F, Montalvo-Ortiz W, Sepulveda MA, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 210, (9):1695–710 (2013). doi: 10.1084/jem.20130579 [Google Scholar]
  21. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 206, (8):1717–25 (2009). doi: 10.1084/jem.20082759 [Google Scholar]
  22. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 33, (17):1889–94 (2015). doi: 10.1200/JCO.2014.56.2736 [Google Scholar]
  23. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26, :677–704 (2008). doi: 10.1146/annurev.immunol.26.021607.090331 [CrossRef] [PubMed] [Google Scholar]
  24. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 19, (7):813–24 (2007). doi: 10.1093/intimm/dxm057 [Google Scholar]
  25. Taube JM, Anders RA, Young GD, Xu H, Sharma R, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4, (127):127-37 (2012). doi: 10.1126/scitranslmed.3003689 [Google Scholar]
  26. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 8, (8):793–800 (2002). doi: 10.1038/nm730 [Google Scholar]
  27. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2, (3):261–8 (2001). doi: 10.1038/85330 [Google Scholar]
  28. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 173, (2):945–54 (2004). doi: 10.4049/jimmunol.173.2.945 [Google Scholar]
  29. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 6, :6692 (2015). doi: 10.1038/ncomms7692 [Google Scholar]
  30. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366, (26):2443–54 (2012). doi: 10.1056/NEJMoa1200690 [Google Scholar]
  31. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369, (2):134–44 ( 2013). doi: 10.1056/NEJMoa1305133 [Google Scholar]
  32. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 379, (4):341–51 (2018). doi: 10.1056/NEJMoa1805131 [Google Scholar]
  33. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 375, (19):1823–33 (2016). doi: 10.1056/NEJMoa1606774 [CrossRef] [PubMed] [Google Scholar]
  34. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 373, (19):1803–13 (2015). doi: 10.1056/NEJMoa1510665 [Google Scholar]
  35. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372, (4):311–9 (2015). doi: 10.1056/NEJMoa1411087 [Google Scholar]
  36. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 387, (10031):1909–20 (2016). doi: 10.1016/S0140-6736(16)00561-4 [Google Scholar]
  37. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 377, (20):1919–29 (2017). doi: 10.1056/NEJMoa1709937 [Google Scholar]
  38. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, (10):1374–85 (2016). doi: 10.1016/S1470-2045(16)30364-3 [Google Scholar]
  39. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 16, (9):563–80 (2019). doi: 10.1038/s41571-019-0218-0. [Google Scholar]
  40. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168, (4):707–23 (2017). doi: 10.1016/j.cell.2017.01.017 [Google Scholar]
  41. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 118, (1):9–16 (2018). doi: 10.1038/bjc.2017.434 [Google Scholar]
  42. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348, (6230):124–8 (2015). doi: 10.1126/science.aaa134 [Google Scholar]
  43. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 16, (11):2598–2608 (2017). doi: 10.1158/1535-7163.MCT-17-0386 [Google Scholar]
  44. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 31, (5):711–723 (2017).e4. doi: 10.1016/j.ccell.2017.04.003 [Google Scholar]
  45. Mariathasan S, Turley S J, Nickles D, Castiglioni A, Yuen K, et al. TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 554, (7693):544–548 (2018). doi: 10.1038/nature25501 [Google Scholar]
  46. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 39, (1):1–10 (2013). doi: 10.1016/j.immuni.2013.07.012 [Google Scholar]
  47. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity. Nature. 523, (7559):231–5 (2015). doi: 10.1038/nature14404 [Google Scholar]
  48. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 375, (9):819–29 (2016). doi: 10.1056/NEJMoa1604958 [Google Scholar]
  49. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, et al. Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation. Nat Commun. 8, (1):1136 (2017). doi: 10.1038/s41467-017-01062-w [Google Scholar]
  50. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 7, (2):188–201 (2017). doi: 10.1158/2159-8290.CD-16-1223 [Google Scholar]
  51. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, et al. Loss of IFN-y pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 167, (2):397–404 (2016).e9. doi: 10.1016/j.cell.2016.08.069 [Google Scholar]
  52. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for immunotherapy. Nat Rev Clin Oncol. 16, (6):356–371 (2019). doi: 10.1038/s41571-019-0175-7 [Google Scholar]
  53. Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 5, (1):3–8 (2017). doi: 10.1158/2326-6066.CIR-16-0297 [Google Scholar]
  54. DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 19, (6):369–382 (2019). doi: 10.1038/s41577-019-0127-6 [Google Scholar]
  55. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 7, (3):264–276 (2017). doi: 10.1158/2159-8290.CD-16-0828 [Google Scholar]
  56. Verdegaal EME, de Miranda NFCC, Visser M, Trajanoski Z, Zemanova M, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 536, (7614):91–5 (2016). doi: 10.1038/nature18945 [Google Scholar]
  57. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 7, :10501 (2016). doi: 10.1038/ncomms10501 [Google Scholar]
  58. Fourcade J, Sun Z, Benallaoua M, Guillaume P, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 207, (10):2175–86 (2010). doi: 10.1084/jem.20100637 [Google Scholar]
  59. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, (4):917–27 (2012). doi: 10.1158/0008-5472.CAN-11-1620 [Google Scholar]
  60. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 26, (6):923–37 (2014). doi: 10.1016/j.ccell.2014.10.018 [Google Scholar]
  61. Lines JL, Sempere LF, Broughton T, Wang L, Noelle RJ. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74, (7):1924–32 (2014). doi: 10.1158/0008-5472.CAN-13-1509 [Google Scholar]
  62. Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 52, (1):17–35 (2020). doi: 10.1016/j.immuni.2019.12.011 [Google Scholar]
  63. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 107, (9):4275–80 (2010). doi: 10.1073/pnas.0914296107 [Google Scholar]
  64. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 373, (1):23–34 (2015). doi: 10.1056/NEJMoa1504030 [Google Scholar]
  65. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, (14):1345–56 (2017). doi: 10.1056/NEJMoa1709684 [Google Scholar]
  66. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 386, (1):24–34 (2022). doi: 10.1056/NEJMoa2113044 [Google Scholar]
  67. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 17, (2):97–111 (2017). doi: 10.1038/nri.2016.107 [Google Scholar]
  68. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 31, :51–72 (2013). doi: 10.1146/annurev-immunol-032712-100008 [Google Scholar]
  69. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 13, (1):54–69 (2007). doi: 10.1038/nm1523 [Google Scholar]
  70. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 378, (22):2078–92 (2018). doi: 10.1056/NEJMoa1801005 [Google Scholar]
  71. Paz-Ares L, Mezger J, Garcia-Finana M, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 379, (21):2040–51 (2018). doi: 10.1056/NEJMoa1810865 [Google Scholar]
  72. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. The role of angiogenesis in cancer therapy. Cell. 174, (5):1063–5 (2018). doi: 10.1016/j.cell.2018.08.044 [Google Scholar]
  73. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 380, (12):1116–27 (2019). doi: 10.1056/NEJMoa1816714 [Google Scholar]
  74. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 382, (20):1894–905 (2020). doi: 10.1056/NEJMoa1915745 [Google Scholar]
  75. Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 41, (5):843–52 (2014). doi: 10.1016/j.immuni.2014.10.019 [Google Scholar]
  76. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 203, (5):1259–71 (2006). doi: 10.1084/jem.20052494 [Google Scholar]
  77. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 366, (10):925–31 (2012). doi: 10.1056/NEJMoa1112824 [Google Scholar]
  78. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 379, (24):2342–52 (2018). doi: 10.1056/NEJMoa1809696 [Google Scholar]
  79. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 372, (26):2521–32 (2015). doi: 10.1056/NEJMoa1503093 [Google Scholar]
  80. Sullivan RJ, Gagnon G, Gunturi A, Sullivan L, et al. Atezolizumab plus Cobimetinib and Vemurafenib in BRAF-mutated Melanoma. Nat Med. 25, (6):929–35 (2019). doi: 10.1038/s41591-019-0413-0 [Google Scholar]
  81. Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 7, (1):278 (2019). doi: 10.1186/s40425-019-0768-9 [Google Scholar]
  82. Le DT, Uram JN, Wang H, Bartlett BR, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 372, (26):2509–20 (2015). doi: 10.1056/NEJMoa1500596 [Google Scholar]
  83. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357, (6349):409–13 (2017). doi: 10.1126/science.aan6733 [Google Scholar]
  84. McGrail DJ, Mezger J, et al. Proteogenomic analysis of non-small-cell lung cancer reveals molecular subtypes and associated therapeutic targets. Cancer Cell. 39, (2):224–39 (2021).e8. doi: 10.1016/j.ccell.2020.12.003 [Google Scholar]
  85. Prabhash K, Dhamne M, Vijay A, Babu G, et al. Immune checkpoint inhibitors in the Indian subcontinent: A consensus statement by the Indian Society of Medical and Pediatric Oncology (ISMPO). South Asian J Cancer. 8, (1):59–64 (2019). doi: 10.4103/sajc.sajc_187_18 [Google Scholar]
  86. Kumar L. Cancer, morbidity and mortality in India. Indian J Med Paediatr Oncol. 41, (1):1 (2020). doi: 10.4103/ijmpo.IJMPO_143_19 [Google Scholar]
  87. Haanen J, Carbonnel F, Robert C, Kerr KM, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28, (suppl_4):iv119-iv42 (2017). doi: 10.1093/annonc/mdx225 [Google Scholar]
  88. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 36, (17):1714–28 (2018). doi: 10.1200/JCO.2017.77.6385 [Google Scholar]
  89. Routy B, Le Chatelier E, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 359, (6371):91–7 (2018). doi: 10.1126/science.aan3706 [Google Scholar]
  90. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 359, (6371):104–8 (2018). doi: 10.1126/science.aap9962 [Google Scholar]
  91. Anderson KG, Stromnes IM, Greenberg PD. Obstacles to CAR T-cell therapy for solid tumors. Nat Cancer. 1, (1):18–28 (2020). doi: 10.1038/s43049-019-0005-6. [Google Scholar]
  92. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular cancer. 18, (1):10 (2019)Jan 15. [Google Scholar]
  93. Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews Immunology. 20, (1):25–39 (2020) Jan. [Google Scholar]
  94. Zhang Y, Simoff MJ, Ost D, Wagner OJ, Lavin J, Nauman B, Hsieh MC, Wu XC, Pettiford B, Shi L. Understanding the patient journey to diagnosis of lung cancer. BMC cancer. 21, (1):402 (2021) Apr 14. [Google Scholar]
  95. Bucur A, van Leeuwen J, Christodoulou N, Sigdel K, Argyri K, Koumakis L, Graf N, Stamatakos G. Workflow-driven clinical decision support for personalized oncology. BMC medical informatics and decision making. 16, (Suppl 2):87 (2016) Jul 21. [Google Scholar]
  96. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 36, (17):1714–68 (2018) Jun 10. [Google Scholar]
  97. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The oncologist. 13, (S4):2–9 (2008) Oct 1. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.